At a glance
ClinicalIndex Comparison RecordN/ACompleted· 28 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Active Surveillance to Monitor the Real World Safety in Indian Patients Prescribed Nintedanib for the Treatment of Locally Advanced, Metastatic or Locally Recurrent Non Small Cell Lung Cancer (NSCLC) of Adenocarcinoma Tumor Histology After First Line Chemotherapy
In Brief
An observational study for Non-small Cell Lung Cancer. Completed, enrolled 28 participants across 11 sites.
Detailed Summary
This active surveillance aims to collect the safety data of 100 NSCLC patients treated with nintedanib per the approved Indian label within 2 years from the date of commercial availability of the drug in India (23rd January 2017). The objective is to look at the safety of nintedanib in the real world setting.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer
CountriesIndia
Collaborators--
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedJan 2017
Enrollment StartFeb 2017
Primary CompletionSep 2022
TodayJul 2026
First PostedJan 11, 2017
Enrollment StartFeb 28, 2017
Primary CompletionSep 24, 2022
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 9.5 years ago